0001562180-18-001897.txt : 20180417 0001562180-18-001897.hdr.sgml : 20180417 20180417122011 ACCESSION NUMBER: 0001562180-18-001897 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180416 FILED AS OF DATE: 20180417 DATE AS OF CHANGE: 20180417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Velleca Mark A. CENTRAL INDEX KEY: 0001706847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 18758347 MAIL ADDRESS: STREET 1: 79 TW ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 79 T.W. ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: P. O. BOX # 110341 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2018-04-16 false 0001560241 G1 Therapeutics, Inc. GTHX 0001706847 Velleca Mark A. C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR. 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 true true false false President and CEO Common Stock 2018-04-16 4 M false 7500.00 3.72 A 7500.00 D Common Stock 2018-04-16 4 S false 7000.00 35.9452 D 500.00 D Common Stock 2018-04-16 4 S false 500.00 36.71 D 0.00 D Stock Options (Right to Buy) 3.72 2018-04-16 4 M false 7500.00 0.00 D 2025-12-21 Common Stock 7500.00 151933.00 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The price represents the weighted average price with a low of $35.62 and a high of $36.45. The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. /s/ Peter N. Cunningham, attorney-in-fact 2018-04-17